1. This study examined the effects of altering nitric oxide levels with sodium nitroprusside or L-arginine in rat hearts stored hypothermically.
INTRODUCTION
Cardioplegic arrest and storage in a modified saline at low temperature are used to ensure the viability of human hearts until transplantation can be achieved, usually 60 % and 40 % of normal systolic contractile function respectively after normothermic reperfusion, but coronary flow values always remained substantially reduced ( 40 %). Previous studies have attributed this decreased flow to the effects of both hypothermia and hyperkalaemia on the coronary endothelium [2k4] . Both a lack of nitric oxide (NO) and excessive production of NO have been implicated in various types of myocardial injury. Moreover, a loss of endothelium-dependent vasodilatation and of NO release occurs in hearts that have been subjected to hypothermic preservation and then reperfused, and these have been held at least partly responsible for reperfusion injury under these circumstances [5] . Inhibitors of NO synthase, however, can sometimes protect against ischaemia-reperfusion injury, suggesting that NO is partly responsible for the injury [6k8]. However, all these studies have been carried out in hearts subjected to short periods of cardioplegic ischaemia and reperfusion. Such hearts may not resemble those stored for a longer period before reperfusion. Since NO-mediated vasodilatation is attenuated after cold cardioplegia and early reperfusion [4] , as well as in hearts stored for a prolonged period, we decided to evaluate the effect of blocking NO synthase activity during a period of prolonged hypothermic preservation. We have monitored the functional capability of the stored rat heart during subsequent normothermic reperfusion. We have also investigated the effect of sodium nitroprusside (SNP), an NO donor, on the ability of stored hearts to recover normal mechanical function after long-term hypothermic storage.
METHODS

Isolated heart preparations
Mature female Sprague-Dawley rats (200-250 g) were used for these experiments. Hearts were excised and placed in ice-cold Krebs-Henseleit buffer (KHB) to produce cardiac arrest. Within 1 min of excision, the aorta was dissected free of extraneous tissue, cannulated, and then rapidly connected to a Langendorff perfusion apparatus. Hearts were perfused thereafter either in Langendorff mode or working heart mode with KHB containing 118.5 mM NaCl, 4.75 mM KCl, 1. In Langendorff mode, hearts were retrogradely perfused with KHB through the aorta at a constant perfusion pressure of 75 mmHg. After 5 min a latex balloon connected to a polyethylene catheter was inserted through the left atrium into the left ventricle for measurement of left ventricular developed pressure (LVDP, peak systolic pressure minus end-diastolic pressure). The balloon was expanded with water to give an end-diastolic pressure of 5 mmHg on a Bell and Howell pressure transducer (type 4327L).
In another series of experiments, hearts were initially perfused in Langendorff mode for 5 min, during which time the left atrium was cannulated. A working heart preparation was then established by perfusing the left atrium with KHB at a filling pressure of 20 mmHg. The left ventricle ejected against a constant pressure in the aorta of 75 mmHg. Aortic flow (AF) was measured with an electromagnetic flow probe (Cardiovascular Instruments, model N-37695) placed around the aorta just beyond the origin of the coronary arteries and previously calibrated by timed volumetric collection of perfusate. Coronary flow (CF) was measured by timed collections of coronary effluent.
The heart rate was determined from a cardiac electrogram using two wire electrodes, one placed on the right atrium and the other in a small (10 ml) cylindrical bath into which the coronary perfusate was allowed to drip. The apex of the heart was immersed in the fluid collecting in this bath.
The cardiac electrogram, plus LVDP and its differential (at a frequency response of 115 Hz), were recorded using a 4-channel Lectromed Multitrace heated-stylus recorder. All hearts were allowed a stabilization period of 15 min before acquisition of data began, which continued thereafter for a further 60 min. Hearts with a CF greater than 20 ml\min or a heart rate of less than 240 beats\min at the end of the initial 5 min of Langendorff perfusion were rejected from the study.
Hypothermic preservation
Hearts that were to be stored were first perfused in Langendorff mode with the above solution for 5 min. The aortic cannula was then connected to a peristaltic pump and the organ slowly microperfused at 0.3 ml\min for 24 h at 4 mC, as described by Wicomb and Collins [9] . The term microperfusion is used to describe a very low rate of perfusion used during hypothermic preservation, and should be distinguished from the conventional continuous normothermic perfusion. The composition of the storage solution was as follows : 110 mM NaCl, 6 .48 mM KCl, 6 mM MgSO % , 0.05 mM CaCl # , 25 mM NaHCO $ , 1.18 mM KH # PO % , 11.1 mM glucose, 2.0 mM sodium pyruvate, 1 % polyethylene glycol (2000) and insulin, 5 units\l. The pH was adjusted to 7.4 and the osmolarity of the medium was 320 mosmol\l. To this solution was added either 3 mM L-arginine methyl ester (L-NAME) or 1.6 mM SNP or 250 mM dexamethasone.
Establishment of the optimal doses of L-NAME
Preliminary experiments were performed to find a dose of L-NAME that would inhibit NO synthase without exerting a significant decrease in CF. Three different doses (0.5, 3 and 10 mM) of L-NAME were added to the medium that was used to perfuse freshly isolated hearts in Langendorff mode. In this study, 3-mM L-NAME caused a decrease in CF of 20 % without significantly decreasing LVDP and was used routinely thereafter. A higher concentration of L-NAME (10 mM) produced a 50 % reduction in CF and decreased LVDP by 35 % during 60 min of normothermic perfusion. Doses of L-arginine and dexamethasone tested in this study were similar to those used in earlier studies [10k13] .
Rewarming
At the end of the 24-h period of hypothermic storage, each heart was rewarmed to 37 mC using KHB. Aortic pressures were progressively raised from 30 mmHg to 75 mmHg over a 15-min period. Data were collected thereafter for a further 60 min. Each heart was reperfused either in Langendorff mode or in working heart mode. In those hearts reperfused in Langendorff mode, a latex balloon for measuring LVDP was inserted into the left ventricle via the left atrium after 10 min of rewarming and the end-diastolic pressure readjusted to 5 mmHg. At the end of reperfusion, hearts were freeze-clamped with Wollenberger tongs that had been precooled in liquid nitrogen. Tissues were kept frozen thereafter until used for biochemical analysis. For comparative purposes, some hearts (n l 6) were microperfused at 4 mC for 24 h but not rewarmed. Other hearts (n l 6) were perfused for 60 min without hypothermic preservation. In addition, a group of hearts (n l 10) was analysed when freshly isolated from the animal.
Biochemical analysis
The ATP and creatine phosphate (CP) contents of frozen tissue samples were determined enzymically with a Perkin Elmer 561 spectrophotometer according to the method of Jaworek and Welsh [10] . Specimens from the left ventricular apex were taken for analysis either immediately after harvest, at the end of 60 min of normothermic perfusion, at the end of hypothermic storage, or at the end of reperfusion.
Myocardial water content
Weighed left ventricular muscle was dried and the percentage water content calculated as follows :
Wet weightkDry weight Wet weight i100
Experimental groups
Eleven experimental groups were studied. Group I (n l 10) consisted of fresh unstored hearts and served as the control group. Hearts in group II (n l 6) were stored but otherwise untreated, while hearts in group III (n l 6) were stored in normal buffer but reperfused with L-NAME (3 mM). Hearts in groups IV and V (n l 6 in both) were stored in untreated buffer and reperfused with either SNP (16 mM) or L-arginine (10 mM) respectively. Hearts in groups VI (n l 6) and VII (n l 6) were stored with Larginine or SNP (1.6 mM) and reperfused with untreated KHB. Group VIII hearts (n l 6) were stored with dexamethasone (250 mM) and reperfused with untreated buffer. Hearts in group IX (n l 6) were microperfused with dexamethasone (250 mM) during and after storage, while hearts in groups X (n l 6) and XI (n l 6) were stored with dexamethasone (250 mM) but reperfused with KHB containing either L-arginine (3 mM) or SNP (16 mM) respectively.
Statistics
Data are presented as meanspS.E.M. The ATP and CP contents of hearts microperfused for 24 h, but not rewarmed, were compared with values from control hearts frozen immediately after isolation from the animal. The ATP and CP contents of hearts that were reperfused for 60 min after hypothermic microperfusion were also compared with those of unstored hearts that had been perfused for 60 min before freeze-clamping. Comparisons of high-energy phosphate levels were also carried out between groups stored in different solutions. All comparisons of those parameters measured over time were performed using a two-way repeated measures analysis of variance in order to test for group differences over time. If significance was detected (P 0.05 for the associated F value), further comparisons among groups at each individual time point were performed to determine at which time points differences existed. If more than two groups were compared to a single control group, analysis was performed using a Dunnett's t-test for the appropriate number of comparisons. In comparisons involving only two groups, an unpaired Student's t-test was used. Comparisons of parameters not measured over time were performed using a factorial analysis of variance investigation, followed by a Dunnett's t-test if more than two groups were compared with a single control group, or using an unpaired Student's t-test if only two groups were compared. All t-test comparisons performed were two tailed. Statistical analyses were made with a Macintosh computer using StatView SEj Graphics (Abacus Concepts, Berkeley, CA, U.S.A.) and Multistat software (Biosoft, Cambridge, U.K.). A value of P 0.05 was considered to be statistically significant.
Drugs used
Dexamethasone was purchased from ICN Biomedicals. All other drugs were purchased from Sigma Co. Ltd.
RESULTS
Two percent of all hearts harvested failed to meet the criteria for inclusion in this study. Figure 1 shows the LVDP values of freshly isolated hearts and of those hearts stored at 4 mC for 24 h, after which they were reperfused at 37 mC for 60 min in Langendorff mode. LVDP values of hearts that were stored and then rewarmed were significantly lower than those obtained from non-stored hearts at all time points studied. Hearts that were stored in untreated buffer and later reperfused in solutions containing SNP or Larginine (groups IV and V) had higher but not significantly different LVDP values during reperfusion, when compared with those hearts stored and normothermically reperfused with untreated buffer (group II). Hearts reperfused with L-NAME after storage in untreated buffer (group III) had the lowest LVDP values. Hearts hypothermically microperfused with buffer containing either L-arginine or SNP, and normothermically reperfused with untreated buffer (groups VI and VII), had the highest LVDP values of all the stored hearts. The LVDP values of hearts microperfused for 24 h with dexamethasone and reperfused with normal buffer (group VIII) and those hearts stored and reperfused in the presence of dexamethasone (group IX) were low but they were not significantly different from values attained by hearts in group II. Inclusion of dexamethasone in the storage buffer also had no significant effect on the LVDP values of hearts normothermically reperfused with either SNP or L-arginine.
Left ventricular developed pressure
End-diastolic pressure
End-diastolic pressure values of all hearts hypothermically microperfused for 24 h and then reperfused (with or without drugs) were significantly higher than those of non-stored hearts at all time points during the 60-min period of normothermic reperfusion in Rat heart preservation with nitric oxide donors Langendorff mode. However, end-diastolic pressure values were highest in hearts that were microperfused with buffer alone during storage, but later reperfused with a normothermic buffer containing L-NAME (33p2.1 mmHg).
Coronary flow
This study was principally aimed at determining what effect, if any, manipulation of NO levels with SNP or Larginine had on CF after hypothermic storage of hearts. Figure 2 shows CF values of unstored hearts and hearts microperfused for 24 h at 4 mC before being reperfused in Langendorff mode at normothermia for 60 min. In reference hearts, CF (16.2p1.5 ml\min) was decreased by about 20 % in the presence of 3 mM L-NAME, and was slightly increased by inclusion of SNP (to 17.4p1.4 ml\min) or L-arginine (to 17.0p0.9 ml\min) in the perfusion buffer. Hearts stored and then normothermically reperfused with an untreated buffer (group II) showed a CF value of 4.1p1.3 ml\min. Hearts reperfused with L-NAME after storage (group III) had very poor coronary flows, while hearts reperfused with SNP or L-arginine in the buffer (groups IV and V ) showed peak CF values which were higher, but not significantly different from those of group II hearts (Figure 2 ). Hearts stored with SNP or L-arginine in the buffer and then reperfused with untreated buffer (groups VI and VII ) showed peak CF values which were not significantly different from those of control hearts (group I). Inclusion of dexamethasone in the perfusion buffer either during or after the period of storage (groups VIII and IX) had no significant effect on CF when compared with the group II hearts. Hearts stored with dexamethasone and then normothermically reperfused with buffer containing SNP (group X) or L-arginine (group XI) showed similar CF values to those of group IV or V hearts. Table 1 shows the haemodynamic performance of rat isolated hearts perfused in working mode either before or after the period of storage. Compared with the control unstored hearts (group I), all stored hearts showed both a lower AF and cardiac output. Decreases in AF and cardiac output were significant in all groups except for those perfused with either SNP or L-arginine (groups IV to VII). The highest AF value seen during reperfusion was in hearts stored with L-arginine and then reperfused with an untreated buffer (59 % of control value). Hearts stored with an untreated buffer and then reperfused with Table 2 Myocardial contents of ATP and CP (µmol/g dry weight) in unstored hearts and in hearts after 24 h of cold preservation with and without a period of normothermic reperfusion in Langendorff mode or in working heart mode Statistical significance : *P 0.05 compared with reference hearts ; †P 0.05 compared with hearts stored in buffer alone at corresponding time point. Table 2 shows that ATP and CP concentrations of freshly isolated hearts were 28.4p1.8 and 36.4p2.8 µmol\g dry weight respectively, and that after 1 h of normothermic perfusion in Langendorff mode the ATP and CP concentrations of unstored hearts were only slightly reduced (to 21.1p2.2 and 25.2p2.4 µmol\g dry weight respectively). The ATP and CP concentrations of unstored hearts perfused for 60 min in Langendorff mode were not significantly different from those of hearts perfused in working mode ( Table 2 ). The ATP and CP concentrations of freshly isolated hearts were not significantly affected by perfusion with SNP, L-arginine or dexamethasone (being in the ranges of 27.6-28.5 and 34-37.1 µmol\g dry weight respectively). ATP and CP concentrations at the end of cold storage were generally somewhat lower than in fresh hearts in all groups (Table  2) . Hearts in groups II, III, VIII and IX, however, had significantly reduced ATP levels at the end of the period of cold storage ( Table 2 ). The ATP concentrations of hearts stored with, or normothermically reperfused with, buffers containing either SNP or L-arginine (groups IV to VII), were somewhat higher than those of hearts perfused with untreated buffer or with a buffer containing L-NAME. This was true both at the end of hypothermic storage and at the end of normothermic reperfusion (Table 2) . CP concentrations at the end of storage were very low in all stored hearts. During normothermic reperfusion CP concentrations remained steady or fell slightly. Resynthesis of CP in hearts of groups II, III, VIII and IX did not even keep pace with utilization. Hearts stored in buffers containing SNP or L-arginine, however, showed the highest ATP and CP concentrations. They also showed the highest AF and cardiac output values among all the groups of stored and reperfused hearts, although in some cases this superiority was not statistically significant. It is pertinent to note, however, that it was these groups of hearts which also showed the highest LVDP values 30-40 min after starting normothermic reperfusion in Langendorff mode ( Figure  1 ).
Working hearts
High-energy phosphate analysis
DISCUSSION
In order to realize our goal of obtaining a consistently successful long-term preservation of isolated hearts, anything that compromises either the structure or function of stored hearts during preservation must be identified and circumvented. Most obviously, CF in hearts stored for a long period in crystalloid buffers is known to be severely reduced upon reperfusion [1,13k15] and this has been attributed both to myocyte swelling [15] and to damage to the endothelial monolayer [16] , particularly its glycocalyx [17] . Damage to the endothelium by crystalloid solutions may manifest itself as an impairment of endothelium-dependent relaxation in both large arteries and microvessels, possibly through a reduction in NO production [5] .
A major finding of this study is that inclusion of either SNP or L-arginine in the buffer used for storing rat isolated hearts can greatly improve CF during subsequent normothermic reperfusion, and this suggests that for optimum benefit, L-arginine or SNP must be given during the period of hypothermic ischaemic storage. In a related study, Amarani et al. [18] showed that in rat hearts subjected to cardioplegic arrest, there was improved CF and better mechanical function when hearts were treated with L-arginine. However, Engelman et al. [19] reported that L-arginine was most beneficial when given before or during the period of cardioplegic arrest, but was actually detrimental during reperfusion. During hypothermic storage, clearly the heart is ischaemic. Moreover, myocardial ischaemia impairs NO synthesis in hearts that are subjected to ischaemia and then reperfused [6] , and this loss of basal NO production seems to contribute to ischaemic injury. Hence, supplementing NO production with NO donors should increase the level of NO and thus relax coronary arterioles during the period of ischaemia. It is surprising and unexplained that reperfusion of stored hearts in the presence of NO donors failed to significantly improve CF in the experiments of Engelman et al. [19] . During reperfusion, the production of superoxide radicals is increased [20] , and this may further decrease the steady-state concentration of NO through the formation of peroxynitrite. Peroxynitrite is a potent oxidant that may mediate free-radical-induced damage. Since the relaxation of microvessels is primarily due to a release of NO, it is to be expected that NO donors like SNP will increase CF. The observation that CF values did not significantly increase in our stored hearts or in the experiments of Engelman et al. [19] suggests either that the vessels were damaged and unresponsive to NO, or that decreased NO levels may not have been responsible for the low flows.
Several previous studies have found that crystalloid cardioplegic solutions can cause significant injury to endothelial cells, with gross deformity to their flow surfaces. Damage to endothelial cells may then induce a calcium-independent form of NO synthase in smooth muscle [21] . Induction of this enzyme, therefore, may further worsen an already compromised myocardium. It is, of course, unclear from our studies whether this enzyme was actually induced, but there are previous reports suggesting that inhibitors of NO synthase can protect against ischaemia-reperfusion injury in the heart [8, 22, 23] .
The glucocorticoid dexamethasone has been shown previously to inhibit the induction in vitro of a calciumindependent form of NO synthase in vascular endothelial cells [24] . In this study, hearts exposed to dexamethasone either during and\or after storage did not show any significant improvement either in CF values or in contractility. This suggests that NO synthase was either not induced or that dexamethasone was ineffective in preventing enzyme induction under our experimental conditions. Cyclic GMP is a second messenger involved in some NO-mediated effects. In our experiments, the low CF observed after reperfusion may be due to a low level of this second messenger. On the other hand, other possible mechanisms can lead to relaxation of blood vessels. Gu et al. [25] showed that hearts stored with nicorandil, a drug which can stimulate guanylate cyclase in addition to opening K ATP channels [26, 27] , had a significantly higher CF after storage compared with hearts stored without nicorandil. There was no significant difference, however, in the level of cGMP in the two groups. During cold storage, therefore, the K ATP channel effect of nicorandil appears to be more prominent than its ability to stimulate guanylate cyclase. It will be interesting to determine whether the effects of NO donors in stored hearts can be blocked by K ATP channel blockers.
Depletion of adenine nucleotide compounds, resulting from a loss of membrane integrity, and hence causing some organelle dysfunction, seems to be a critical factor delaying left ventricular recovery during reperfusion. In the present study, differences seen in the high-energy phosphate levels measured at the end of cold preservation, or at the end of reperfusion, did not account for differences in the capacity to recover mechanically. Different groups of stored hearts showed statistically insignificant differences in the levels of ATP and CP, both at the end of storage and at the end of reperfusion. In all groups, the concentrations of both of the highenergy phosphates were quite low, compared with the values from freshly isolated hearts, and the concentrations seen at the end of reperfusion were not significantly different from those at the end of storage.
The observed differences in functional recovery of our stored hearts, therefore, seemingly relate to effects brought about by L-arginine and SNP during storage that are unrelated to stores of ATP and CP. It remains unclear just how SNP and L-arginine exert their protective effects upon the myocardium.
